Four drug company sales reps charged July 3 in indictments and criminal informations filed by the Justice Department in Harrisburg, Penn. federal court. Named were William Hoover (Lederle), Paul Carls (Squibb), Michael Stephan (McNeil) and David Snyder (Fleming Co.). Four Pennsylvania pharmacists were also named. Justice reports that the charges, which each carry a maximum sentence of 10 years in prison and $250,000 fine, represent the first prosecutions under the drug diversion law. Arraignment has been scheduled for July 19.
You may also be interested in...
ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.
The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.